Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease ; volume:15 ; number:1 ; day:18 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
Nature Communications ; 15, Heft 1 (18.11.2024), 1-10, 12.2024

Creator: Hofmann, Anna
Häsler, Lisa M.
Lambert, Marius
Kaeser, Stephan A.
Gräber-Sultan, Susanne
Obermüller, Ulrike
Kuder-Buletta, Elke
la Fougere, Christian
Laske, Christoph
Vöglein, Jonathan
Levin, Johannes Martin
Fox, Nick C.
Ryan, Natalie S.
Zetterberg, Henrik
Llibre-Guerra, Jorge J.
Perrin, Richard J.
Ibanez, Laura
Schofield, Peter R.
Brooks, William S.
Day, Gregory S.
Farlow, Martin R.
Allegri, Ricardo F.
Chrem Mendez, Patricio
Ikeuchi, Takeshi
Kasuga, Kensaku
Lee, Jae-Hong
Roh, Jee Hoon
Mori, Hiroshi
Lopera, Francisco
Bateman, Randall J.
McDade, Eric
Gordon, Brian A.
Chhatwal, Jasmeer P.
Jucker, Mathias
Schultz, Stephanie A.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-024-52937-8

URN: urn:nbn:de:101:1-2502042119451.900199452624

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hofmann, Anna
Häsler, Lisa M.
Lambert, Marius
Kaeser, Stephan A.
Gräber-Sultan, Susanne
Obermüller, Ulrike
Kuder-Buletta, Elke
la Fougere, Christian
Laske, Christoph
Vöglein, Jonathan
Levin, Johannes Martin
Fox, Nick C.
Ryan, Natalie S.
Zetterberg, Henrik
Llibre-Guerra, Jorge J.
Perrin, Richard J.
Ibanez, Laura
Schofield, Peter R.
Brooks, William S.
Day, Gregory S.
Farlow, Martin R.
Allegri, Ricardo F.
Chrem Mendez, Patricio
Ikeuchi, Takeshi
Kasuga, Kensaku
Lee, Jae-Hong
Roh, Jee Hoon
Mori, Hiroshi
Lopera, Francisco
Bateman, Randall J.
McDade, Eric
Gordon, Brian A.
Chhatwal, Jasmeer P.
Jucker, Mathias
Schultz, Stephanie A.
SpringerLink (Online service)

Other Objects (12)

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Related objects

Reset password